Original scientific paper
Superiority of Mi-ADMS to DMSA as parenteral treatment for decreasing mercury (203hg) body burden in rats
K. Kostial
; Institute for Medical Research and Occupational Health, Zagreb, Croatia
M. Blanuša
; Institute for Medical Research and Occupational Health, Zagreb, Croatia
M. Piasek
; Institute for Medical Research and Occupational Health, Zagreb, Croatia
I. Šimonović
; Medical Faculty, University of Zagreb, Zagreb, Croatia
M.M. Jones
; Vanderbilt University, Nashwille, Tennessee, USA
P.K. Singh
; Vanderbilt University, Nashwille, Tennessee, USA
Abstract
The efficiency of meso-2,3-dirnercaptosuccinic acid (DMSA) and the mono-isoamyl ester of meso-2,3-dimercaptosuccinic acid (Mi-ADMS) in decreasing 203Hg retention was evaluated in rats in relation to age and time of treatment. The experiments were performed on six-week- and seven- day-old Wistar rats, which received 203Hg by intraperitoneal administration. The chelators DMSA or Mi-ADMS were also administered intraperitoneally, twice, on two consecutive days, in doses of 0.25 mmol/kg body weight as early (0.5 and 24 h) or delayed treatment (24 and 48 h, or 48 and 72 h) after 203Hg administration. The retention of 203Hg was determined in the carcass, liver, kidneys and brain six days after administration using gamma scintillation counters (double crystal, well type). In all experimental conditions, regardless of the animals' age and time of chelation therapy, Mi-ADMS was found to be superior to DMSA in reducing the body burden of 203Hg in whole body and organs. Mi-ADMS therefore seems to be a very promising chelator in the treatment of mercury poisoning.
Keywords
age; chelation therapy; delayed treatment; immediate treatment; mercury poisoning; radioactiviy determination; radionuclide administration
Hrčak ID:
147227
URI
Publication date:
26.1.1994.
Visits: 1.334 *